Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca
University of California, San Diego
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Regeneron Pharmaceuticals
Hoosier Cancer Research Network
H. Lee Moffitt Cancer Center and Research Institute
Assistance Publique - Hôpitaux de Paris
MultiVir, Inc.